Longitudinal changes in cell-mediated immunity after varicella-zoster virus skin test in the general population; Shozu Herpes Zoster Study: SHEZ study.
antigen
cell-mediated immunity
cohort study
general population
herpes zoster
persistence
skin test
varicella-zoster virus
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
28
06
2022
received:
12
03
2022
accepted:
21
11
2022
pubmed:
24
11
2022
medline:
11
1
2023
entrez:
23
11
2022
Statut:
ppublish
Résumé
Varicella-zoster virus-specific cell-mediated immunity has been associated with the onset and severity of herpes zoster (HZ), and the administration of the HZ vaccine enhanced the immunity. However, limited data is available on the duration of cell-mediated immunity enhancement by soluble antigen of varicella-zoster virus (VZV) skin test. A prospective, community-based cohort study was conducted in Shozu County, Kagawa Prefecture, Japan. Repeated VZV skin tests containing inactivated VZV antigen and blood tests were performed on 365 subjects aged 60 years and older at baseline, 1, 2, and 3 years later. The differential immunity indices of VZV over time for cell-mediated and humoral immunity were evaluated. VZV skin test reaction and ELISpot counts increased significantly at 1, 2, and 3 years later compared to the baseline. However, humoral immunity indices did not change materially over time. Soluble antigen by VZV skin test enhanced VZV-specific cell-mediated immunity, and it persisted for at least 1 year. In addition, the inoculation with inactivated antigens every year by VZV skin test continued to enhance VZV-specific cell-mediated immunity after 2 and 3 years.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28336Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Cohen JI. Herpes zoster. N Engl J Med. 2013;369:255-263.
Donahue JG. The incidence of herpes zoster. Arch Intern Med. 1995;155:1605-1609.
Toyama N, Shiraki K. Epidemiology of herpes zoster and its relationship to varicella in Japan: a 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol. 2009;81:2053-2058.
Koshy E, Mengting L, Kumar H, Jianbo W. Epidemiology, treatment and prevention of herpes zoster: a comprehensive review. Indian J Dermatol Venereol Leprol. 2018;84:251-262.
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-2284.
Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55:1320-1328.
Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10:e1001420.
Tseng HF, Harpaz R, Luo Y, et al. Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. J Infect Dis. 2016;213:1872-1875.
Baxter R, Bartlett J, Fireman B, et al. Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study. Am J Epidemiol. 2018;187:161-169.
Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev. 2003;8:223-246.
Takao Y, Miyazaki Y, Onishi F, et al. The shozu herpes zoster (SHEZ) study: rationale, design, and description of a prospective cohort study. J Epidemiol. 2012;22:167-174.
Asada H. VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: the SHEZ study. Vaccine. 2019;37:6776-6781.
Kamiya H, Ihara T, Hattori A, et al. Diagnostic skin test reactions with varicella virus antigen and clinical application of the test. J Infect Dis. 1977;136:784-788.
Asano Y, Shiraki K, Takahashi M, Nagai H, Ozaki T, Yazaki T. Soluble skin test antigen of varicella-zoster virus prepared from the fluid of infected cultures. J Infect Dis. 1981;143:684-692.
Smith JG, Liu X, Kaufhold RM, Clair J, Caulfield MJ. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella zoster virus. Clin Diagn Lab Immunol. 2001;8:871-879.
Sadaoka K, Okamoto S, Gomi Y, et al. Measurement of Varicella-Zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-γ enzyme-linked immunospot assay. J Infect Dis. 2008;198:1327-1333.
Takahashi M, Okada S, Miyagawa H, et al. Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine. 2003;21:3845-3853.
Shiraki K, Okuno T, Yamanishi K, Takahashi M. Polypeptides of varicella-zoster virus (VZV) and immunological relationship of VZV and herpes simplex virus (HSV). J Gen Virol. 1982;61:255-269.
Kamiya H, Asano Y, Ozaki T, et al. Varicella vaccine potency and stability during transport and delivery. Kansenshogaku Zasshi. 2011;85:161-165.
Okuno Y, Takao Y, Miyazaki Y, et al. Assessment of skin test with varicella-zoster virus antigen for predicting the risk of herpes zoster. Epidemiol Infect. 2013;141:706-713.
Tang H, Moriishi E, Okamoto S, et al. A community-based survey of varicella-zoster virus-specific immune responses in the elderly. J Clin Virol. 2012;55:46-50.
Shirane R, Tang H, Hayashi K, et al. Relationship between cell-mediated immunity to varicella-zoster virus and aging in subjects from the community-based Shozu Herpes Zoster Study. J Med Virol. 2017;89:313-317.
Takao Y, Miyazaki Y, Okeda M, et al. Incidences of herpes zoster and postherpetic neuralgia in Japanese adults aged 50 years and older from a community-based prospective cohort study: the SHEZ study. J Epidemiol. 2015;25:617-625.
Morrison VA, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60:900-909.
Gershon AA. Varicella vaccine-are two doses better than one? N Engl J Med. 2002;347:1962-1963.
Vermeulen JN, Lange JMA, Tyring SK, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine. 2012;30:904-910.
Levin MJ, Schmader KE, Pang L, et al. Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults. J Infect Dis. 2016;213:14-22.
Weinberg A, Popmihajlov Z, Schmader KE, et al. Persistence of varicella-zoster virus cell-mediated immunity after the administration of a second dose of live herpes zoster vaccine. J Infect Dis. 2019;219:335-338.
Esser MT, Marchese RD, Kierstead LS, et al. Memory T cells and vaccines. Vaccine. 2003;21:419-430.
Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087-2096.
Chiyaka ET, Nghiem VT, Zhang L, Deshpande A, Mullen PD, Le P. Cost-effectiveness of herpes zoster vaccination: a systematic review. Pharmacoeconomics. 2019;37:169-200.